Omrix Biopharmaceuticals, Inc. Announces Interim Analysis Indicating Superiority Of Fibrin Pad Versus SURGICEL In Mild To Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

Omrix Biopharmaceuticals, Inc. (OMRI) Announces Interim Analysis Indicating Superiority Of Fibrin Pad Versus SURGICEL In Mild To Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials
10/8/2008

NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc. (“Omrix”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today interim results from its U.S. Phase II clinical trial evaluating the safety and hemostatic effectiveness of the Company’s Fibrin Pad product candidate as an adjunct to control mild to moderate soft tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic surgery. The Company also provided an update on additional Fibrin Pad clinical trials, including the Phase II study being conducted in Israel in severe bleeding.

Read at BioSpace.com

• BioSpace.com

• Omrix Biopharmaceuticals, Inc.

• Clinical - Phase II

• Bleeding